Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Never miss an Options trading signal: Unusual Options Activity and Options Screeners with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Cm Life Sciences III Inc (CMLTU)

Cm Life Sciences III Inc (CMLTU)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]

Fundamentals

See More
  • Market Capitalization, $K N/A
  • Shares Outstanding, K N/A
  • Annual Sales, $ 0 K
  • Annual Income, $ 0 K
  • 60-Month Beta N/A
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book N/A
Trade CMLTU with:
  • Price/Earnings ttm N/A
  • Earnings Per Share ttm N/A
  • Most Recent Earnings N/A on N/A
  • Latest Earnings Date N/A
  • Annual Dividend & Yield N/A (N/A)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Price Performance

See More
Period Period Low Period High Performance
1-Month
8.58 +3.38%
on 12/17/21
10.41 -14.79%
on 11/23/21
-1.53 (-14.71%)
since 11/17/21
3-Month
8.58 +3.38%
on 12/17/21
10.60 -16.32%
on 09/30/21
-1.41 (-13.72%)
since 09/17/21

Most Recent Stories

More News
EQRx and CM Life Sciences III Announce Effectiveness of Form S-4 Registration Statement and Stockholder Meeting Details to Vote on Proposed Business Combination

EQRx, a new type of pharmaceutical company committed to developing and delivering important new medicines to patients at radically lower prices, and CM Life Sciences III Inc. (Nasdaq: CMLTU), a life science-focused...

CMLTU : 8.87 (-6.53%)
EQRx to Present at the 4th Annual Evercore ISI HealthCONx Conference

EQRx, a new type of pharmaceutical company committed to developing and delivering important new medicines to patients at radically lower prices, today announced that management will participate in a fireside...

CMLTU : 8.87 (-6.53%)
EQRx Announces Partnership Agreement with Abdul Latif Jameel Health to Commercialize Lead Oncology Programs in Middle East, Turkey and Africa

EQRx, a new type of pharmaceutical company committed to developing and delivering important new medicines to patients at radically lower prices, today announced a strategic collaboration agreement with...

CMLTU : 8.87 (-6.53%)
EQRx and Evotec Announce Integrated Drug Discovery and Development Partnership

EQRx, a new type of pharmaceutical company committed to developing and delivering important new medicines to patients at radically lower prices, and Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX,...

EVO : 7.15 (-1.24%)
CMLTU : 8.87 (-6.53%)
Evotec and EQRx Announce Integrated Drug Discovery and Development Partnership

- EQRX TO LEVERAGE EVOTEC'S UNIQUE DATA-DRIVEN INTEGRATED DRUG DISCOVERY AND DEVELOPMENT ACCELERATOR PLATFORM - PARTNERSHIP AIMS TO BUILD UP JOINTLY OWNED PIPELINE TO DELIVER INNOVATIVE, AFFORDABLE AND...

EVTCY : 22.9600 (-0.04%)
EVO : 7.15 (-1.24%)
CMLTU : 8.87 (-6.53%)
EQRx Launches “Remaking Medicine: On The Record” Investor Video Series

EQRx, a new type of pharmaceutical company committed to developing and delivering important new medicines to patients at radically lower prices, today launched a multi-part corporate video series entitled...

CMLTU : 8.87 (-6.53%)
EQRx and NHSE Sign Memorandum of Understanding to Enter into England’s First Population Health Partnership for Cancer Drugs

EQRx, a new type of pharmaceutical company committed to developing and delivering important new medicines to patients at radically lower prices, today announced it has signed a memorandum of understanding...

CMLTU : 8.87 (-6.53%)
EQRx and Absci Announce Partnership to Discover and Develop Next-Generation Protein-Based Drugs

EQRx, a new type of pharmaceutical company committed to developing and delivering important new medicines to patients at radically lower prices, and Absci Corporation (Nasdaq: ABSI), the drug and target...

CMLTU : 8.87 (-6.53%)
ABSI : 4.97 (-6.05%)
EQRx Appoints Kathy Giusti to Board of Directors

EQRx, a new type of pharmaceutical company committed to developing and delivering important new medicines to patients at radically lower prices, today announced the appointment of Kathy Giusti to the Company’s...

CMLTU : 8.87 (-6.53%)
EQRx Announces Presentation of Phase 3 Data Demonstrating a Progression-Free Survival Benefit with Sugemalimab Consolidation Therapy in Patients with Stage III NSCLC at ESMO Congress 2021

EQRx, a new type of pharmaceutical company committed to developing and delivering important new medicines to patients at radically lower prices, today announced a late-breaking mini oral presentation of...

CMLTU : 8.87 (-6.53%)
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar